Get the Stockscreener App
8.71
1.00%
0.0859
After Hours:
8.71
Addex Therapeutics Ltd Adr Stock (ADXN) Latest News
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Addex Stock Soars on Crucial Update From Indivior Research Deal - MSN
Golden Heaven Group secures investment of $25.2M - MSN
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 - GlobeNewswire Inc.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Are Medical Stocks Lagging Boston Scientific (BSX) This Year? - Yahoo Finance
Drug discovery and bringing new medicine to marketthe future of AI in pharma - OutSourcing-Pharma.com
What Makes Addex Therapeutics (ADXN) a New Buy Stock - Yahoo Finance
Earnings call: Addex Therapeutics reports half-year financials and R&D updates By Investing.com - Investing.com South Africa
Earnings call: Addex Therapeutics reports half-year financials and R&D updates - Investing.com
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Zacks Investment Research
ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week High at $19.42 - MarketBeat
ADXN Stock on the Rise: A Promising Investment - The InvestChronicle
There Are Mixed Signals on the Chart for Addex Therapeutics Ltd ADR (ADXN) - US Post News
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Alcon (ALC) Outperforming Other Medical Stocks This Year? - Yahoo Canada Finance
Addex’s Partner Discontinues ADX71149 development in Epilepsy - GlobeNewswire Inc.
Addex Therapeutics presents results from GABAB PAM cough program - TipRanks
Addex Presents Positive Results from GABAB PAM Cough - GlobeNewswire Inc.
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) - GlobeNewswire Inc.
Addex to Participate at the Benchmark Company Healthcare House Call Conference - The Globe and Mail
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Canada Shine On
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results - Investing.com India
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results By Investing.com - Investing.com
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug - Yahoo Movies UK
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Addex Therapeutics Receives Nasdaq Approval for ADS Ratio Change By Investing.com - Investing.com India
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo New Zealand News
Addex Therapeutics ADR (NASDAQ: ADXN) Has Moved an M4 PAMS Program to Optimization - BP Journal
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
ASLAN Pharma (NASDAQ:ASLN) Stock Quotes, Forecast and News Summary - Benzinga
Addex Therapeutics (ADXN) Stock Price, News & Analysis - MarketBeat
ADXN Stock Price and Chart — SIX:ADXN - TradingView
Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A ... - Yahoo Eurosport UK
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):